SpaceX (SPCX) Is Down 31% From Its High and Is Now Borrowing $25 Billion. Should Investors Be Worried?

SpaceX is under pressure despite its recent IPO, with shares down 31% from a high of about $225 to $154 and the company carrying significant new debt, including a $20 billion bridge loan due in 2027 and $25 billion raised in a debt sale. The article highlights a steep valuation of roughly $2 trillion, 77x sales, net losses, and heavy AI-related spending, arguing the stock is highly speculative and vulnerable to dilution. While long-term upside is possible, the piece advises investors to wait for a much lower entry point.

Analysis

The market is effectively valuing a pre-earnings, highly capital-intensive platform at a multiple that assumes near-perfect execution across launch cadence, Starlink monetization, and a still-unproven AI buildout. The second-order issue is not just valuation compression; it is capital structure creep. When a company with large fixed-asset needs starts leaning on both debt and equity at the same time, incremental returns on new capital tend to reset lower, and the equity becomes a residual claim on an increasingly levered enterprise.

The more interesting read-through is to the adjacent names: AI infrastructure beneficiaries may see near-term demand from this capex cycle, but they also inherit the same overbuild risk if multiple private and public platforms race to add compute at once. NVDA is the cleanest direct beneficiary only if deployments convert into sustained utilization; otherwise the market will eventually distinguish between booked capex and actual demand, which can pressure the entire AI supply chain with a 6-18 month lag.

From a trading perspective, the move lower may not be done because this is a classic long-duration asset with sentiment tied to financing conditions, not quarterly results. Any additional debt raise, governance headline, or delay in the AI roadmap is a catalyst for another leg down, while only a visible inflection in free cash flow would stabilize the stock. The contrarian view is that the market may be underestimating how much strategic optionality a large cash balance buys, but that optionality is only worth something if management resists dilution and shows capital discipline — both currently unclear.

The cleaner expression is to avoid chasing upside in the common equity and instead wait for a financing-related dislocation. If management continues to fund expansion through debt before profits, equity holders are effectively selling volatility to the company, and history says that rarely pays unless operating leverage arrives faster than expected.

Key Decisions for Investors

• Avoid initiating long exposure in the stock for now; wait 1-3 quarters for proof of free-cash-flow inflection before reconsidering, because current upside is dominated by multiple risk rather than fundamentals.
• If a rally follows any financing headline, use it to initiate a tactical short or buy puts with 3-6 month tenor; the highest-probability catalyst is another debt/equity raise that widens dilution fears.
• Pair trade: long NVDA / short the speculative AI-funding vehicle on a 6-12 month horizon, but size modestly because NVDA only works if the capex wave converts into utilization rather than capacity gluts.
• For investors wanting exposure to the theme, express it through better-capitalized AI beneficiaries rather than the most levered platform; preferred entry is on broad market weakness, not on financing-driven strength.
• Set a trigger to revisit if management demonstrates two consecutive quarters of improving gross margin and operating cash flow; absent that, treat the equity as a financing story, not a compounder.